Zoundream - Revolutionary technology for the early detection of infant health problems

In a world where infant health is of paramount importance, Zoundream has developed a ground-breaking AI solution that revolutionises the early detection of pathologies and developmental disorders. By leveraging the world's largest cry database, Zoundream enables accurate detection, analysis and translation of infant cries. Roberto Iannone, CEO of Zoundream talks about his motivation for founding the company, current and potential customers and their vision for the future.

How would you explain your solution in three sentences to a professional colleague from the health sector?

"Zoundream has developed an AI solution leveraging the world's largest cry database, enabling precise detection, analysis, and translation of infant cries. This tool supports early pathology and neurodevelopmental disorder detection, thereby enhancing global family welfare by facilitating caregiving and supporting healthcare professionals."

What problem motivated you to start the company?

"Infant pathologies and developmental disorders are often discovered too late, leading to lifelong consequences. On average, these issues are found when the child is 3-4 years old. With Zoundream's groundbreaking technology, we can detect potential issues in infants as young as 6 months old, allowing for early intervention and much improved long-term outcomes."

How do you convince a pharmaceutical company, a health insurance company or another potential client to set up a pilot project with you?

"Our pioneering AI technology, supported by an extensive database of infant cries, distinguishes us in the industry. Its superior accuracy surpasses competitors. Our commitment to rigorous clinical research and validation further fortifies the credibility and effectiveness of our solution.

Robust partnerships with industry leaders like hospitals and insurance firms establish us as frontrunners in infant health monitoring tech. With a skilled team proficient in business, AI, software development, and clinical research, we possess a formidable advantage.

Moreover, our solution's versatility enables seamless integration into any microphone-equipped device, expanding its potential and accessibility.

We've conducted pilots with Generali Assicurazioni. Our initial pilot with Generali yielded data for refining our cry analysis algorithm, assessing market potential, and gathering user feedback, laying a solid foundation. Now, we are discussing with them to explore using our device for telemedicine, given its user-friendly design and data accuracy."

Who are your current customer (groups) and who do you want your potential customers to be?

"As a health-tech firm, we're strategically partnering with hospitals, insurers, and home healthcare providers to expand our reach and seamlessly integrate our technology into healthcare systems. We're actively solidifying relationships with hospitals and insurers to establish leadership in infant health monitoring. Additionally, we're exploring collaborations with providers of complementary products like infant sleep monitors and telemedicine platforms. Our recent launches in Europe (Q4-2023) and North America (Q1-2024) are just the beginning, with plans to enter China by Q2-2024, followed by expansions into South America and Australia, demonstrating our global commitment."

Where do you see yourself in 3 years and how can 5-HT support you?

"In 3 years, I see Zoundream leading innovative clinical trials and piloting our medical device for early detection of pathologies and neurodevelopmental disorders, adhering to the FDA regulations. 5-HT's support can foster vital partnerships, facilitating market entry and revenue generation thorugh the uimplementation of telemedecine inititives like those with Generali Assicurazioni."